Avalyn Pharma moved closer to the public markets by targeting an IPO raise of about $182 million, aiming to take inhaled reformulations of approved respiratory medicines into late-stage clinical development. The company’s plans focus on supporting Phase 3 studies and progressing commercial readiness for its platform of inhaled therapies. The IPO push comes as respiratory drug developers continue to pursue reformulated options intended to improve delivery and usage profiles. For market watchers, Avalyn’s stated net proceeds depend on pricing and offer terms, but the funding target signals confidence in the clinical and commercial path for inhaled assets. Separately, the pipeline momentum around inhaled reformulations is also reflected in sector commentary around late-stage study plans for products derived from previously approved molecules.